Abstract
The COVID-19 [1] pandemic has forced governments to take measures to contain the spread of the disease [2]; however, the effects have varied significantly from one country to another contingent on governments’ responses. Countries that have flattened their coronavirus curves prove that interventions can bring COVID-19 under control. These achievements hold lessons, such as the strict social distancing and coordinated efforts of all government levels in China and massive testing in South Korea, for other countries battling the coronavirus around the world. In this work, we attempt to estimate how many COVID-19 cases could have been prevented in the United States (US) when compared with the US’s actual number of cases assuming that on a certain date, the US took China-like or South Korea-like interventions and that these interventions would have been as effective in the US as in China and South Korea. We found that if that date was at the early stage of the outbreak (March 10), more than 99% (1.15 million) fewer infected cases could be expected by the end of the epidemic. This number decreases to 66.03% and 73.06% fewer infected cases with the China-like scenario and the South Korea-like scenario, respectively, if actions were taken on April 1, highlighting the need to respond quickly and effectively to fight the virus. Furthermore, we found that although interventions in both China and South Korea allowed the COVID-19 outbreak to be managed, the epidemic could still oscillate without strict large-scale ‘lockdown’ measures, as shown in South Korea. Our results demonstrate that early effective interventions can save considerably more people from infection and provide a worldwide alert regard the need for swift response.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is jointly supported by the National Natural Science Foundation of China under grant nos. 41330423 and 41420104006.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
A report on the raw data and a way of sharing those cases with generation labels will be published elsewhere; prior to their publication, a very rough version can be obtained at GitHub(https://github.com/Bigger-Physics/COVID19-reducedcases) or via email request.
